8- cyclohexyl- N- ((dimethylamino)sulfonyl)- 1,1a,2,12b- tetrahydro- 11- methoxy- 1a- ((3- methyl- 3,8- diazabicyclo(3.2.1)oct- 8- yl)carbonyl)cycloprop(d)indolo(2,1- a)(2)benzazepine- 5- carboxamide

an NS5B inhibitor and antiviral agent

Also Known As:

BMS-791325; beclabuvir

Networked: 33 relevant articles (2 outcomes, 10 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Indoles: 200
      - 8-cyclohexyl-N-((dimethylamino)sulfonyl)-1,1a,2,12b-tetrahydro-11-methoxy-1a-((3-methyl-3,8-diazabicyclo(3.2.1)oct-8-yl)carbonyl)cycloprop(d)indolo(2,1-a)(2)benzazepine-5-carboxamide: 33
    - Benzazepines: 5
      - 8-cyclohexyl-N-((dimethylamino)sulfonyl)-1,1a,2,12b-tetrahydro-11-methoxy-1a-((3-methyl-3,8-diazabicyclo(3.2.1)oct-8-yl)carbonyl)cycloprop(d)indolo(2,1-a)(2)benzazepine-5-carboxamide: 33

Experts

1.	McPhee, Fiona: 9 articles (09/2018 - 02/2014)
2.	Chayama, Kazuaki: 5 articles (01/2020 - 03/2017)
3.	Yin, Philip D: 5 articles (12/2017 - 05/2015)
4.	Eley, Timothy: 5 articles (02/2016 - 02/2014)
5.	Kumada, Hiromitsu: 4 articles (01/2020 - 03/2017)
6.	Grasela, Dennis M: 4 articles (02/2016 - 02/2014)
7.	Lawitz, Eric: 4 articles (02/2016 - 02/2014)
8.	Sims, Karen D: 4 articles (02/2016 - 02/2014)
9.	Takaguchi, Koichi: 3 articles (08/2019 - 03/2017)
10.	Gardiner, David F: 3 articles (02/2016 - 02/2014)

Related Diseases

1.	Infections 06/01/2014 - "Randomized, placebo-controlled, single-ascending-dose study of BMS-791325, a hepatitis C virus (HCV) NS5B polymerase inhibitor, in HCV genotype 1 infection." 01/01/2015 - "Therefore, beclabuvir represents a powerful weapon against HCV infection and has to be considered an optimal option in tailored IFN-free combinations." 09/01/2018 - "In the UNITY-3 study, 96% sustained virologic response (SVR12) rate was observed in Japanese patients with hepatitis C virus (HCV) genotype (GT)-1 infection treated for 12 weeks with fixed-dose daclatasvir, asunaprevir, and beclabuvir (DCV-TRIO). " 05/05/2015 - "In this open-label, nonrandomized, uncontrolled study, a high rate of SVR12 was achieved in treatment-naive and treatment-experienced noncirrhotic patients with chronic HCV genotype 1 infection who received 12 weeks of treatment with the oral fixed-dose regimen of daclatasvir, asunaprevir, and beclabuvir. " 06/01/2014 - "BMS-791325 safety, pharmacokinetics, and antiviral activity were evaluated in a double-blind, placebo-controlled, single-ascending-dose study in 24 patients (interferon naive and experienced) with chronic HCV genotype 1 infection, randomized (5:1) to receive a single dose of BMS-791325 (100, 300, 600, or 900 mg) or placebo. "
2.	Chronic Hepatitis C 04/01/2018 - "Daclatasvir, asunaprevir and beclabuvir fixed-dose combination for patients with genotype 1 chronic hepatitis C." 01/01/2018 - "Combined daclatasvir (DCV)/asunaprevir (ASV) plus beclabuvir (BCV) treatment shows a high virological response for genotype 1b chronic hepatitis C patients. " 12/01/2017 - "Daclatasvir/asunaprevir/beclabuvir, all-oral, fixed-dose combination for patients with chronic hepatitis C virus genotype 1." 05/01/2015 - "A randomized trial of daclatasvir in combination with asunaprevir and beclabuvir in patients with chronic hepatitis C virus genotype 4 infection." 08/01/2019 - "Real-world virological efficacy and safety of daclatasvir/asunaprevir/beclabuvir in patients with chronic hepatitis C virus genotype 1 infection in Japan."
3.	Fibrosis (Cirrhosis) 05/05/2015 - "Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis." 02/01/2014 - "We analyzed data from 66 treatment-naive patients with HCV genotype 1 infection without cirrhosis who were assigned randomly to groups given daclatasvir (60 mg, once daily), asunaprevir (200 mg, twice daily), and BMS-791325 (75 or 150 mg, twice daily) for 12 or 24 weeks. " 05/05/2015 - "In this open-label uncontrolled study, patients with chronic HCV genotype 1 infection and cirrhosis who received a 12-week oral fixed-dose regimen of daclatasvir, asunaprevir, and beclabuvir, with or without ribavirin, achieved high rates of SVR12." 09/01/2018 - "Potent viral suppression and improvements in alpha-fetoprotein and measures of fibrosis in Japanese patients receiving a daclatasvir/asunaprevir/beclabuvir fixed-dose combination for the treatment of HCV genotype-1 infection." 12/01/2017 - "This multinational (Taiwan, South Korea, Russia) phase 3 study evaluated the all-oral, ribavirin-free, fixed-dose combination (DCV-TRIO) of daclatasvir (NS5A inhibitor) 30 mg, asunaprevir (NS3 inhibitor) 200 mg, and beclabuvir (NS5B inhibitor) 75 mg, in patients with chronic hepatitis C virus genotype-1 infection, with or without compensated cirrhosis. "
4.	Hepatitis C 03/25/2015 - "BMS-791325 is a novel hepatitis C NS5B inhibitor which is currently in clinical development. " 03/25/2015 - "Sensitive and accurate liquid chromatography-tandem mass spectrometry methods for quantitative determination of a novel hepatitis C NS5B inhibitor BMS-791325 and its active metabolite in human plasma and urine." 01/01/2015 - "Beclabuvir for the treatment of hepatitis C." 08/05/2019 - "Beclabuvir hydrochloride (BCV) is a marketed product for the treatment of hepatitis C viral infection. " 06/01/2018 - "Pharmacokinetic and pharmacodynamic evaluation of daclatasvir, asunaprevir plus beclabuvir as a fixed-dose co-formulation for the treatment of hepatitis C."
5.	Virus Diseases (Viral Diseases) 08/05/2019 - "Beclabuvir hydrochloride (BCV) is a marketed product for the treatment of hepatitis C viral infection. " 01/01/2016 - "Asunaprevir (ASV), daclatasvir (DCV), and beclabuvir (BCV) are three drugs developed for the treatment of chronic hepatitis C virus infection. "

Related Drugs and Biologics

1.	asunaprevir
2.	daclatasvir
3.	Ribavirin (Virazole)
4.	Interferons
5.	Protease Inhibitors (Protease Inhibitor)
6.	Antiviral Agents (Antivirals)
7.	Nucleosides
8.	Sofosbuvir
9.	dasabuvir
10.	ombitasvir

Related Therapies and Procedures

1.	Drug Tapering
2.	Therapeutics